参考文献/References:
[1] Gloviczki ML,Saad A,Textor SC. Blood oxygen level-dependent (BOLD) MRI analysis in atherosclerotic renal artery stenosis[J]. Curr Opin Nephrol Hypertens,2013,22(5):519-524.[2] Dobrek L. An outline of renal artery stenosis pathophysiology—A narrative review[J]. Life(Basel),2021,11(3):208.[3] Lal H,Singh P,Ponmalai K,et al. Role of blood oxygen level-dependent magnetic resonance imaging in studying renal oxygenation changes in renal artery stenosis[J]. Abdom Radiol(NY),2022,47(3):1112-1123.[4] Martins-Oliveira A,Guimaraes DA,Ceron CS,et al. Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension[J]. Eur J Pharmacol,2018,821:97-104.[5] Safian RD. Renal artery stenosis[J]. Prog Cardiovasc Dis,2021,65:60-70.[6] Lenz T. [Treatment of renal artery stenosis in the year 2021][J]. Internist (Berl),2021,62(3):252-262.[7] Abene EE,Gimba ZM,Edah JO,et al. Blood pressure control and kidney damage in hypertension: Results of a three-center cross-sectional study in North Central Nigeria[J]. Niger J Clin Pract,2020,23(11):1590-1597.[8] Cooper EL,Xie Y,Nguyen H,et al. Early rapid decline in kidney function in medically managed patients with atherosclerotic renal artery stenosis[J]. J Am Heart Assoc,2019,8(11):e012366.[9] Hricik DE,Browning PJ,Kopelman R,et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney[J]. N Engl J Med,1983,308(7):373-376..[10] Herrmann SM,Textor SC. Current concepts in the treatment of renovascular hypertension[J]. Am J Hypertens,2018,31(2):139-149.[11] Koratala A,Chamarthi G,Touyz RM,et al. Renovascular hypertension:one size does not fit all: challenges in diagnosis and management[J]. Hypertension,2021,77(4):1022-1028.[12] Prince M,Tafur JD,White CJ,et al. When and how should we revascularize patients with atherosclerotic renal artery stenosis?[J]. JACC Cardiovasc Interv,2019,12(6):505-517.[13] Triantis G,Chalikias GK,Ioannidis E,et al. Renal artery revascularization is a controversial treatment strategy for renal artery stenosis: a case series and a brief review of the current literature[J]. Hellenic J Cardiol,2022,65:42-48.[14] Bhalla V,Textor SC,Beckman JA,et al. Revascularization for renovascular disease: a scientific statement from the American Heart Association[J] .Hypertension,2022,79(8):e128-e143.[15] Peng M,Ji W,Jiang X,et al. Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: two-year results[J]. Int J Cardiol,2016,205:117-123.[16] de Bhailis á,Al-Chalabi S,Hagemann R,et al. Managing acute presentations of atheromatous renal artery stenosis[J]. BMC Nephrol,2022,23(1):1-9.[17] Manohar S,Hamadah A,Herrmann SM,et al. Total renal artery occlusion: recovery of function after revascularization[J]. Am J Kidney Dis,2018,71(5):748-753.[18] Abumoawad A,Saad A,Ferguson CM,et al. Tissue hypoxia,inflammation,and loss of glomerular filtration rate in human atherosclerotic renovascular disease[J]. Kidney Int,2019,95(4):948-957.[19] 中国医疗保健国际交流促进会血管疾病高血压分会专家共识起草组. 肾动脉狭窄的诊断和处理中国专家共识[J]. 中国循环杂志,2017,32(9):10.[20] Li LP,Hack B,Seeliger E,et al. MRI mapping of the blood oxygenation sensitive parameter T2* in the kidney: basic concept[J]. Methods Mol Biol,2021,2216:171-185.[21] Lin Z,Zhang B,Lin L,et al. Blood oxygen level dependent magnetic resonance imaging to predict split renal function improvement after renal artery stenting[J]. Eur J Vasc Endovasc Surg,63(4):659-660.[22] Zhao L,Li G,Meng F,et al. Cortical and medullary oxygenation evaluation of kidneys with renal artery stenosis by BOLD-MRI[J]. PloS One,2022,17(3):e0264630.[23] Lerman LO. Cell-based regenerative medicine for renovascular disease[J]. Trends Mol Med,2021,27(9):882-894. [24] Textor SC,Lerman LO. Paradigm shifts in atherosclerotic renovascular disease: where are we now?[J]. J Am Soc Nephrol,2015,26(9):2074-2080.[25] Simeoni M,Borrelli S,Garofalo C,et al. Atherosclerotic-nephropathy: an updated narrative review[J]. J Nephrol,2021,34(1):125-136.[26] Textor SC,Abumoawad A,Saad A,et al. Stem cell therapy for microvascular injury associated with ischemic nephropathy[J]. Cells,2021,10(4):765.[27] Ishiuchi N,Nakashima A,Doi S,et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats[J]. Stem Cell Res Ther,2020,11(1):130.[28] Wang W,Sai WL,Yang B. [The role of macrophage polarization and interaction with renal tubular epithelial cells in ischemia-reperfusion induced acute kidney injury][J]. Sheng Li Xue Bao,2022,74(1):28-38.[29] Ferguson CM,Farahani RA,Zhu XY,et al. Mesenchymal stem/stromal cell-derived extracellular vesicles elicit better preservation of the intra-renal microvasculature than renal revascularization in pigs with renovascular disease[J]. Cells,2021,10(4):763.[30] Tanriover C,Copur S,Ucku D,et al. The mitochondrion: a promising target for kidney disease[J]. Pharmaceutics,2023,15(2):570.[31] Engel JE,Williams E,Williams ML,et al. Targeted VEGF (Vascular Endothelial Growth Factor) therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization[J]. Hypertension,2019,74(5):1113-1123.[32] Miao C,Zhu X,Wei X,et al. Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases[J]. Ren Fail,2022,44(1):881-892.
相似文献/References:
[1]董佳佳 于子翔 马依彤.冠状动脉慢性完全闭塞病变血运重建的治疗[J].心血管病学进展,2020,(8):794.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.003]
DONG Jiajia,YU Zixiang,MA Yitong.Therapeutic Strategy of Revascularization in Patients with Chronic Complete Occlusion[J].Advances in Cardiovascular Diseases,2020,(7):794.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.003]
[2]范子胤 彭瑜 张钲.心肌梗死相关性心源性休克血运重建的研究进展[J].心血管病学进展,2021,(5):417.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.008]
FAN Ziyin,PENG Yu,ZHANG Zheng.Revascularization of Myocardial Infarction Associated Cardiogenic Shock[J].Advances in Cardiovascular Diseases,2021,(7):417.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.008]
[3]韩旭 汪蕾 方纬.18F-FDG PET评估存活心肌指导冠状动脉血运重建治疗的研究进展[J].心血管病学进展,2023,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.004]
HAN Xu,WANG Lei,FANG Wei.Coronary Revascularization Therapy Guided by 18F-FDG PET in Evaluating Viable Myocardium[J].Advances in Cardiovascular Diseases,2023,(7):11.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.004]
[4]李婕 李晓梅.血流储备分数及其衍生指标在急性冠脉综合征中的临床应用[J].心血管病学进展,2023,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.011]
LI Jie,LI Xiaomei.Clinical Application of Fractional Flow Reserve and Its Derived Indicators in Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2023,(7):44.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.011]
[5]石秋月 常静 毛敏.肾动脉粥样硬化性狭窄患者肾动脉支架植入术的研究进展[J].心血管病学进展,2023,(5):406.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.006]
SHI Qiuyue,CHANG Jing,MAO Min.Renal Artery Stent Placement in Patients with Atherosclerotic Renal Artery Stenosis[J].Advances in Cardiovascular Diseases,2023,(7):406.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.006]
[6]王章龙 刘瑞麟 张波 周敬群.非罪犯血管病变的评估及其在血运重建中的作用[J].心血管病学进展,2023,(9):845.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.018]
WANG Zhanglong,LIU Ruilin,ZHANG Bo,et al.Evaluation of Non-Culprit Coronary Lesions and Its Role in Revascularization[J].Advances in Cardiovascular Diseases,2023,(7):845.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.018]